ALSG consensus for maintenance therapy after first-line treatment The clinical benefit of rituximab-maintenance therapy following BR and VR-CAP is not convincing. Rituximab-maintenance therapy should be recommended after R-CHOP or cytarabine-containing induction therapy. The choice of rituximab-maintenance therapy in Asian patients should be individualized, and affordability and reimbursement status remain important considerations in the region.